A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) No significant financial relationships to disclose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results